The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study.

background: prostate cancer (PCa) is the second most common neoplasm in male patients. to date, there's no certain indication about the maximum waiting time (WT) acceptable for treatment beginning and the impact on oncological and functional outcomes has not been well established. methods: data from the national research council PCa monitoring multicenter project in Italy (Pros-IT CNR) were prospectively collected and analyzed. WT was defined as the time from the bioptical diagnosis of PCa to the first treatment received. patients were divided in two groups, using a time frame of 90 days. quality of life was measured through the Italian version of the university of california Los angeles-prostate cancer Index (UCLA-PCI) and of the short-form health survey (SF-12). the occurrence of upgrading, upstaging, presence of lymph node metastasis and positive surgical margins at the final histopathological diagnosis, and PSA at 12 months follow-up were evaluated. results: the overall median WT was 93 days. the logistic multivariable model confirmed that age, being resident in southern regions of italy and T staging at diagnosis were significantly associated with a WT>90 days. at 6 months from diagnosis the mean SF-12 score for the emotional-psychological component was significantly lower in WT≥90 days group (P=0.0428). among patients treated with surgical approach, no significant differences in oncological outcomes were found in the two groups. conclusions: In our study age, clinical T stage and provenance from southern regions of Italy are associated with a WT>90 days. WT might have no impact on functional and oncological outcome.